Icariside I

Synonyms: Icarisid I
Icariside I (GH01) 是一种具有口服活性的 Icarlin 代谢产物,通过同时调节成骨细胞和破骨细胞分化改善雌激素缺乏引起的骨质疏松症,促进 ATP (MS-D18391) 或 Nigericin (MS-O56514) 诱导的 mtROS 产生及 NLRP3 炎症小体激活并引起特异质肝毒性,但不改变 NLRC4 和 AIM2 炎性小体的激活,同时通过靶向 IL-6/STAT3 通路抑制乳腺癌的增殖、凋亡 (apoptosis)、侵袭和转移,并作为犬尿氨酸-AhR 通路抑制剂通过阻断肿瘤免疫逃逸来缓解癌症。
产品编号: MS-R98498 纯度: 98.76% CAS No.: 56725-99-6 分子式: C27H30O11 分子量: 530.52
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Icariside I (GH01) 是一种具有口服活性的 Icarlin 代谢产物,通过同时调节成骨细胞和破骨细胞分化改善雌激素缺乏引起的骨质疏松症,促进 ATP (MS-D18391) 或 Nigericin (MS-O56514) 诱导的 mtROS 产生及 NLRP3 炎症小体激活并引起特异质肝毒性,但不改变 NLRC4 和 AIM2 炎性小体的激活,同时通过靶向 IL-6/STAT3 通路抑制乳腺癌的增殖、凋亡 (apoptosis)、侵袭和转移,并作为犬尿氨酸-AhR 通路抑制剂通过阻断肿瘤免疫逃逸来缓解癌症。

生物实验数据

生物活性 Icariside I (GH01) is an orally active metabolite of Icarlin that ameliorates estrogen deficiency-induced osteoporosis by simultaneously modulating osteoblast and osteoclast differentiation, promotes ATP (MS-D18391)- or Nigericin (MS-O56514)-induced mtROS production and NLRP3 inflammasome activation leading to idiosyncratic hepatotoxicity without altering NLRC4 and AIM2 inflammasome activation, inhibits breast cancer proliferation, apoptosis, invasion, and metastasis by targeting the IL-6/STAT3 pathway, and acts as a kynurenine-AhR pathway inhibitor to alleviate cancer by blocking tumor immune evasion.
IC50 & Target

NLRP3

 

体外研究
(In Vitro)

Icariside I (10-40 μM, 1 小时) 在由 ATP (MS-D18391) 和 Nigericin (MS-O56514) 而非 SiO2、Poly(I:C) (MS-H44982) 和胞浆 LPS (MS-X54539) 诱导的 BMDMs 中,可增强 NLRP3 炎症小体活化和线粒体 ROS 生成,但对 NLRC4 和 AIM2 炎症小体活化无影响。
Icariside I (20 μM M, 1 小时) 在 ATP 或 Nigericin 诱导 BMDMs 中可促进 ASC 寡聚化,但对 K+ 外排无影响。
Icariside I (0-100 μM, 12 小时) 在低于 60 μM 的浓度下不会损害 4T1 细胞的活力。
Icariside I (0-40 μM, 1 小时) 抑制 4T1-luc 细胞中的 IL-6/STAT3 信号传导。
Icariside I (0-40 μM, 1-5 天) 在 4T1-luc 细胞中抑制增殖和迁移,降低 MMP2 和 MMP9 的 mRNA 水平。
Icariside I (0-40 μM, 1 小时) 可以阻碍细胞周期并降低细胞周期蛋白 D1、CDK4、bcl-2,并增加 bax mRNA 表达,从而调节 4T1-luc 细胞的增殖和存活。
Icariside I (5-20 μM,24 小时) 可抑制 Kyn-AhR 通路,并降低 B16F10 细胞中的肿瘤细胞活力。
Icariside I (0.1-100 nM) 通过抑制原代 BMMs 中的 MAPK-p38-NFATc1 级联反应来抑制破骨细胞的分化和吸收。
Icariside I (0.1-1000 nM,3-14 天) 在原代 BMMs 中促进成骨细胞的分化和形成,上调 RUNX2 等下游信号因子。

Western Blot Analysis

Cell Line: BMDMs
Concentration: 20 μM
Incubation Time: 1 h
Result: Promoted caspase-1 activation and IL-1β production, was not affected the expression of NLRP3, ASC, pro-IL-1β, and pro-caspase-1 (p45) induced by ATP in LPS-primed.
Had no effect on caspase-1 cleavage, IL-1β secretion and LDH release triggered by SiO2 and poly.
Did not alter caspase-1 cleavage, IL-1β secretion, and LDH release in Pam3CSK4 (MS-Q33038)-primed BMDMs transfected with LPS, did not affect the expression of pro-IL-1β, ASC, NLRP3 and pro-caspase-1.
Did not alter the release of caspase-1 cleavage, IL-1β secretion, LDH and ASC oligomerization release in response to Salmonella typhimurium infection and triggered by Poly (dA:dT) (MS-W72711) transfection, was not affected the expression of NLRP3, ASC, pro-IL-1β and pro-caspase-1 (p45) in cell lysate.
Promoted ATP-induced ASC oligomerization and the production of caspase-1 and IL-1β induced by Nigericin but not SiO2, poly(I:C) and intracellular LPS in LPS-primed.

Western Blot Analysis

Cell Line: 4T1-luc cells
Concentration: 0 μM, 10 μM, 20 μM, 40 μM
Incubation Time: 1 h
Result: Reduced the phosphorylation of STAT3 induced by IL-6, decreased p-STAT3 (Tyr705) exposed to IL-6 (50 ng/mL) after 12 h. Decreased the protein level of vimentin in the presence of IL-6.

Cell Migration Assay

Cell Line: 4T1-luc cells
Concentration: 0 μM, 10 μM, 20 μM, 40 μM
Incubation Time: 1 days, 5 days
Result: Inhibited IL-6-induced wound healing, the development of colonies.

Cell Cycle Analysis

Cell Line: 4T1-luc cells
Concentration: 0 μM, 10 μM, 20 μM, 40 μM
Incubation Time: 1 h
Result: Entered a viable G1 arrest state, decreased IL-6-induced the proliferative phase of the cell cycle (S+G2/M), prevented cells from entering the S phase.

Western Blot Analysis

Cell Line: BMMs
Concentration: 100 nM
Incubation Time: 0 min, 5 min, 15 min, 30 min
Result: Reduced the level of phosphorylated p38 (p-p38) protein, had no change in JNK, P-JNK, ERK 1/2, and P-ERK 1/2 protein levels.
体内研究
(In Vivo)

Icariside I (25-100 mg/kg,腹腔注射,一次) 可在 LPS 介导的特异质型药物性肝损伤 (IDILI) 易感小鼠模型中诱导肝损伤。
Icariside I (25-50 mg/kg,口服,每日一次,27 天) 通过 IL-6/STAT3 通路抑制 4T1 乳腺癌模型中的肿瘤生长和肺转移。
Icariside I (5-20 mg/kg,口服,7 天) 下调 SLC7A8 和 PAT4 转运蛋白及 AhR,从而通过激活 JAK1-STAT1 信号传导抑制 CTL 中的核 PD-1,进而诱导荷瘤小鼠的肿瘤细胞凋亡。
Icariside I (5-50 mg/kg,灌胃,每周 6 天,4 周) 在卵巢切除术 (OVX) 诱发的骨质疏松症小鼠模型中可改善雌激素缺乏引起的骨质疏松症,且没有明显的肝毒性。

Animal Model: LPS-mediated susceptible C57BL/6 mice (Female 6-8-week-old) model of IDILI
Dosage: 25 mg/kg, 50 mg/kg, 100 mg/kg
Administration: i.p., once
Result: Induced the elevation of ALT and AST serum levels, increased the production of IL-1β and TNF-α production.
Did not alter liver tissue structure Icariside I and LPS alone treatment, led to a trend of hepatocyte focal necrosis and inflammatory cell infiltration in the liver tissue used in combination with LPS.
Facilitated the number of macrophages, leucocytes, macrophages and neutrophils used in combination with LPS.
Animal Model: 4T1-luc cells (1 × 105) xenografts BALB/c mice (Female, 6 weeks)
Dosage: 25 mg/kg, 50 mg/kg
Administration: p.o., once a days, 27 days
Result: Reduced tumor weight and tumor volume, reduced phosphorylated STAT3 levels and IL-6.
Decreased the expressions of vimentin, bcl-2, Cyclin D1, and CDK4, increased the expressions of pro-apoptotic proteins bax and cleaved caspase 3.
Reduced lung metastasis and damage, decreased mRNA expression of the invasive proteins MMP9 and vimentin.
Animal Model: Tumor-bearing mice (C57BL/6 female, 18-22 g)
Dosage: 5 mg/kg, 20 mg/kg
Administration: p.o., 7 days
Result: Reduced tumor volume and tumor weight without body weight changes, inhibited tumor cell proliferation and promoted cell shrinkage, nuclear condensation and necrosis of mouse tumor cells.
Restored the size and weight of immune organs (thymus and spleen), alleviated thymus atrophy and splenomegaly in tumor-bearing mice, and improved the total T cells, CD4+T cells, and CD8+T cells and their ratios in the peripheral blood of the tumor group, enhanced the proportion of TILs and CD8+ T cells and up-regulated the CD8+/CD4+ ratio in tumor tissues.
Upregulated mRNAs levels of CCL4 and CCL8 and CXCL9 and CXCL10, as well as IFN-γ and GZMB and CD69 and Klrk1.
Rescued the levels of intermediate metabolites including Trp, Kyn, kynurenic acid, xanthurenic acid, 3 H-KYN, 3-HAA, quinolinic acid and picolinic acid involved in Trp-Kyn pathway in plasma, reduced the levels of Kyn, kynurenic acid and xanthurenic acid and ratio of Kyn to Trp, downregulated mRNA levels of multiple genes including Ido1, Kat1, Kat3, Kmo, Kynu and Ahr involved in Kyn-AhR pathway.
Down-regulated the mRNA level of SLC7A8, PAT4 transporters of Kyn, kynurenic acid and xanthurenic acid, inhibited AhR, down-regulated the mRNA level of PD-1, p27.
Animal Model: OVX-induced osteoporosis mouse (C57BL/6 12 week-old female) model
Dosage: 5 mg/kg, 50 mg/kg
Administration: i.g., 6 days per week, 4 weeks
Result: Improved liver injury, ameliorates estrogen deficiency-induced osteoporosis without significant hepatotoxicity.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 530.52
分子式 C27H30O11
CAS No. 56725-99-6
别名 Icarisid I

储存&溶解度

体内实验配方
10% DMSO+90% Corn oil: < 6.25 mg/mL (11.78 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: < 6.25 mg/mL (11.78 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
10% DMSO+90% Saline: < 6.25 mg/mL (11.78 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
10% DMSO+90% (20% SBE-β-CD in Saline): < 6.25 mg/mL (11.78 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, sealed storage, away from moisture and light

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 62.5 mg/mL (117.81 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.8849 mL9.4247 mL18.8494 mL47.1236 mL
5 mM0.3770 mL1.8849 mL3.7699 mL9.4247 mL
10 mM0.1885 mL0.9425 mL1.8849 mL4.7124 mL
15 mM0.1257 mL0.6283 mL1.2566 mL3.1416 mL
20 mM0.0942 mL0.4712 mL0.9425 mL2.3562 mL
25 mM0.0754 mL0.3770 mL0.7540 mL1.8849 mL
30 mM0.0628 mL0.3142 mL0.6283 mL1.5708 mL
40 mM0.0471 mL0.2356 mL0.4712 mL1.1781 mL
50 mM0.0377 mL0.1885 mL0.3770 mL0.9425 mL
60 mM0.0314 mL0.1571 mL0.3142 mL0.7854 mL
80 mM0.0236 mL0.1178 mL0.2356 mL0.5890 mL
100 mM0.0188 mL0.0942 mL0.1885 mL0.4712 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

Icariside I 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础